Review article devoted to new advances in viral hepatitis. The article stresses progress achieved in the treatment of chronic hepatitis C, including advent of new drugs boceprevir and telaprevir.
Beside the role of viral genotype, viral load, type of treatment response, age, gender, race, body weight and insulin resistance, the role of newly discovered polymorphism of IL-28B is discussed. Also, currently available antiviral drugs against hepatitis B virus - lamivudin, entecavir, adefocir dipivoxil and tenofovir – are discussed as well.